Pfizer Inc. (PFE) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
Pfizer Inc. (PFE) Profile & Business Summary
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Key Information
| Ticker | PFE |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.pfizer.com |
Market Trend Overview for PFE
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-07-17 (ET)
As of 2026-07-17, PFE is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
PFE last closed at 25.05. The price is about 0.7 ATR above its recent average price (24.57), and the market is currently in a sideways market without a clear direction. Price at 25.05 is moving between minor support near 23.62 and minor resistance near 26.54. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear key risk boundary right now.
A systematic trend-activation signal was most recently triggered on 2026-07-16, reflecting a technical shift toward positive directional alignment.
[2026-07-10] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Closing activity showed limited conviction and did not suggest strong overnight positioning.
The model sees a bullish edge, with 55.8% upside probability and a still-actionable balance between confirmation and reversal risk.
Up probability is 55.8%, with predictability at 53% and signal agreement at 86%. Reversal risk is 13%. That suggests the directional case is supported by broad confirmation and still retains usable quality. At the same time, recent price behavior has shown failed reversal memory.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is modestly above the recent estimated cost basis of 24.48, so the recent structure is still on the firmer side. Price is above the main cost band (24.04 to 24.32), and about 78% of recent positioning is already in profit. That supports trend strength, but it also raises the chance of profit-taking if momentum cools. The lower down support area sits around 24.69 to 24.74. It looks more like a first buffer than a major floor. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, the trend still has support, but because the main support sits lower down around 24.69 to 24.74, the key is whether pullbacks remain controlled before dropping back into that zone.